Log in

ASX:BITBiotron Stock Price, Forecast & News

A$0.09
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.09
Now: A$0.09
A$0.10
50-Day Range
A$0.09
MA: A$0.09
A$0.11
52-Week Range
A$0.05
Now: A$0.09
A$0.19
Volume1.03 million shs
Average VolumeN/A
Market Capitalization$65.98 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus. Biotron Limited is based in North Ryde, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9805 0488

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.07 million
Cash FlowA$0.01 per share
Book ValueA$0.01 per share

Profitability

Miscellaneous

Employees3
Market Cap$65.98 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BIT News and Ratings via Email

Sign-up to receive the latest news and ratings for BIT and its competitors with MarketBeat's FREE daily newsletter.

Biotron (ASX:BIT) Frequently Asked Questions

How has Biotron's stock been impacted by COVID-19 (Coronavirus)?

Biotron's stock was trading at A$0.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIT shares have decreased by 18.3% and is now trading at A$0.09. View which stocks have been most impacted by Coronavirus.

Has Biotron been receiving favorable news coverage?

Media stories about BIT stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biotron earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutBiotron.

Who are some of Biotron's key competitors?

What other stocks do shareholders of Biotron own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biotron investors own include TPG Telecom (TPM), Gemfields (GEM), Northern Star Resources (NST), Strike Energy (STX), Rise Gold (RYESD), Prime Financial Group (PFG), Mesoblast (MESO), Canaan (CAN) and ACI Worldwide (ACIW).

Who are Biotron's key executives?

Biotron's management team includes the following people:
  • Dr. Michelle Miller BSc., GCertAppFin, Ph.D., MSc., CEO, MD & Exec. Director
  • Mr. Peter James Nightingale B.Econ, CA, Company Sec. (Age 62)

What is Biotron's stock symbol?

Biotron trades on the ASX under the ticker symbol "BIT."

What is Biotron's stock price today?

One share of BIT stock can currently be purchased for approximately A$0.09.

How big of a company is Biotron?

Biotron has a market capitalization of $65.98 million and generates $1.07 million in revenue each year. Biotron employs 3 workers across the globe.

What is Biotron's official website?

The official website for Biotron is www.biotron.com.au.

How can I contact Biotron?

The company can be reached via phone at 61 2 9805 0488.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.